SCHEMBL973615

SCHEMBL973615

O=C(CCCCCCCCC(=O)Oc1ccccc1C(=O)O)Oc1ccccc1C(=O)O

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.79
KMT2A Q03164 2/20 0.79
MEN1 O00255 1/20 0.79
RECQL P46063 1/20 0.79
HSD17B10 Q99714 7/20 0.59
HPGD P15428 5/20 0.59
ALDH1A1 P00352 8/20 0.58
ESR1 P03372 1/20 0.58
ITGB3 P05106 1/20 0.58
ITGA2B P08514 1/20 0.58
HMGB1 P09429 1/20 0.58
TSHR P16473 1/20 0.58
GGT1 P19440 1/20 0.58
PTGS1 P23219 1/20 0.58
PTGS2 P35354 1/20 0.58
BLM P54132 1/20 0.58
NAPRT Q6XQN6 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
MAPT P10636 1/20 0.56
LMNA P02545 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13109053 1.00 KDM4E (0.79) KDM4EKMT2AMEN1RECQLHSD17B10
SCHEMBL3765406 0.98 KDM4E (0.81) KDM4EKMT2AMEN1RECQLHSD17B10
SCHEMBL9136787 0.95 KDM4E (0.72) KDM4EKMT2AMEN1RECQLHSD17B10
SCHEMBL28878425 0.95 KDM4E (0.72) KDM4EKMT2AMEN1RECQLHSD17B10
SCHEMBL28416086 0.93 KDM4E (0.74) KDM4EKMT2AMEN1RECQLHSD17B10
SCHEMBL727072 0.92 KDM4E (0.88) KDM4EKMT2AMEN1RECQLHSD17B10
SCHEMBL13983812 0.92 KDM4E (0.73) KDM4EKMT2AMEN1RECQLHSD17B10
SCHEMBL1858148 0.92 KDM4E (0.88) KDM4EKMT2AMEN1RECQLHSD17B10
SCHEMBL725982 0.92 KDM4E (0.88) KDM4EKMT2AMEN1RECQLHSD17B10
SCHEMBL16800398 0.92 KDM4E (0.88) KDM4EKMT2AMEN1RECQLHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7875283-B2 A stent coated with hydrophobic polymer having water-labile bonds and strength to withstand forces of the vascular systems and also biodegrades on its surface rather than bulk erosion; mechanical properties; drug delivery; a polyester,-anhydride or -amide having the monomer, trimellitylimidotyrosine ADVANCED CARDIOVASCULAR SYSTEMS, INC. (US) 2011-01-25 US claimed
US-20050232971-A1 Biodegradable polymers for use with implantable medical devices HOSSAINY SYED F 2005-10-20 US claimed
US-7875283-B2 A stent coated with hydrophobic polymer having water-labile bonds and strength to withstand forces of the vascular systems and also biodegrades on its surface rather than bulk erosion; mechanical properties; drug delivery; a polyester,-anhydride or -amide having the monomer, trimellitylimidotyrosine ADVANCED CARDIOVASCULAR SYSTEMS, INC. (US) 2011-01-25 US disclosed
US-20100291181-A1 THERAPEUTIC DEVICES FOR PATTERNED CELL GROWTH RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2010-11-18 US disclosed
US-20100291181-A1 THERAPEUTIC DEVICES FOR PATTERNED CELL GROWTH RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2010-11-18 US disclosed
US-20050232971-A1 Biodegradable polymers for use with implantable medical devices HOSSAINY SYED F 2005-10-20 US disclosed
US-5434166-A Multiple sclerosis ELI LILLY AND COMPANY (US) 1995-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100291181-A1 THERAPEUTIC DEVICES FOR PATTERNED CELL GROWTH MMP1, FGF2, FGF1 KDM4E 2479/4885KMT2A 4326/4885MEN1 4751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.